Esporte Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Announces April 2021 as the Best Revenue Month in Company History

Esporte Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Announces April 2021 as the Best Revenue Month in Company History

Esporte SAN DIEGO, CA, May 11, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary HempMeds® Brasil had its best revenue month ever in Company history in April 2021.

“Our HempMeds Brasil operations have seen a consistent increase over the years. We aim to reach as many consumers in need as possible and last month’s achievements prove that we are continuing to expand our reach to our target audiences,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus.

“I am incredibly proud of the success our HempMeds Brasil team has been able to achieve. As we celebrate our best revenue month in company history, we are scaling our operations in the country, refreshing our consumer-facing website and increasing the size of our facilities in Brazil to meet the needs of our expanding team,” said HempMeds® CEO Raul Elizalde.

“In the coming months, to support our continued growth, we intend to partner with the largest higher education institution in Brazil to educate medical professionals on the potential benefits of cannabidiol (CBD) and are moving forward in securing partnerships with well-respected professional and Olympic athletes,” said HempMeds® Brasil Managing Director Matheus Patelli. “My team has successfully been able to show Brazilian citizens that our products are of the highest quality and trustworthy, just like the people who work at the Company.”

To learn more about HempMeds® Brasil, please visit www.hempmeds.com.br.

About HempMeds® Brasil

HempMeds® Brasil was the first company to receive approval from the National Sanitary Surveillance Agency (Anvisa) to import a product based on cannabidiol, a substance derived from hemp, a plant of the genus Cannabis. Currently, it is authorized to supply its products, which help in the control of diseases such as epilepsy, Parkinson’s, chronic pain and multiple sclerosis, under medical prescription. For these indications, the products can be subsidized by the Brazilian government. HempMeds® Brasil is working on additional approvals for other indications. www.hempmeds.com.br.

About Medical Marijuana, Inc.

We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by

Kannaway® and

HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including

AXIM® Biotechnologies, Inc. and

Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by

CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product

Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.

Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here.

Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

LEGAL DISCLOSURE

Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

CONTACT:

Public Relations Contact:

Kathryn Brown

Account Supervisor

CMW Media

P. 858-264-6600

[email protected]

www.cmwmedia.com

Investor Relations Contact:

P. (858) 283-4016

[email protected]

Read More